The rumblings on Capitol Hill over Biogen Alzheimer’s drug Aduhelm have been growing louder in recent days as lawmakers began speaking out about its lofty price tag and controversial FDA win.
Now two high-ranking Democrats want answers.
The House Committee on Oversight and Reform announced Friday that it will launch an investigation into the Alzheimer’s drug hotly debated FDA approval and pricing.
Spearheaded by Chairwoman Rep. Carolyn Maloney, D-New York, and Rep. Frank Pallone Jr., D-New Jersey, chairman of the House Committee on Energy and Commerce, the inquiry will address “serious concerns about the steep price of Biogen’s new Alzheimer’s drug Aduhelm and the process that led to its approval despite questions about the drug’s clinical benefit,” the lawmakers said.
